Jon Bigelow, Thayer Pond Solutions

Each new president enters the White House with big dreams and unique challenges. For President Joe Biden, 2021 was dominated by the evolving COVID-19 pandemic, an historically difficult transition of power, and a focus on packing an ambitious combination of economic relief, infrastructure investment, and social spending initiatives into a handful of multi-trillion dollar omnibus bills to push through a tightly-divided Congress.

More than 4.6 million people gained health coverage in the United States in 2021 through the Affordable Care Act (ACA) amid the ongoing Covid-19 pandemic, U.S. President Joe Biden said in a statement on December 22.

Jon Bigelow, Thayer Pond Solutions

According to Jon Bigelow, Executive Director of the Coalition for Healthcare Communication, the beginning of the Biden administration has had a largely positive impact on the biopharma industry, notably marked by an effort to “stick to the science”; a fairly efficient roll-out of COVID-19 vaccines that allows reopening of schools and many aspects of normal daily life; and expansion of Affordable Care Act (ACA) coverage. But behind the scenes, pressure continues to build surrounding high prescription drug costs and changes in tax policy.

Sander Flaum, Principal of Flaum Navigators, believes that it’s absolutely essential that healthcare access is improved in the United States, but he has no confidence that anyone in Washington has the courage or clout to enact the substantial changes that need to be made.

R&D success and M&A activity loom as large swing factors for the bio sector in 2017 with the regulatory arena potentially at its most amenable for years.

Whatever comes out of Congress on the “repeal and replace” of the Affordable Care Act (ACA or Obamacare) matters because it will affect the bottom line of the life sciences industry as well as all of its industry partners.

Or, why 2016 might look a little different than 2015 for pharmaceutical marketers.

Executives from the 2015 and 2014 Manny Award winners and finalists share their views on a variety of industry-related topics.

With presidential primaries right around the corner, the cost of prescription drugs is at the top of the public’s healthcare priority list for the President and Congress, according to polling data from the Kaiser Family Foundation.

Many a blog, article, and cover story has focused on the impact (current and future) of healthcare reform. But some interesting healthcare industry changes have been occurring simultaneously with, and are very much accelerated by, the impact of reform. One of these important market changes is the shift from traditional silos of key customer decision-making to a more blended approach to healthcare (and formulary) decision-making.